Key result
TMVI emerges as a minimally invasive alternative to open surgery for extremely high-risk mitral patients.
Why the study?
Mitral valve disease is highly prevalent and many patients are at extremely high risk for open surgical repair or replacement, limiting treatment options.
Transcatheter mitral valve implantation is an emerging technology for patients with mitral valve disease who are at prohibitive risk for conventional open surgery.
May support TMVI consideration in prohibitive-risk mitral disease; leaves open randomized outcome data.
Mitral valve disease is highly prevalent and quickly leads to development of severe heart failure. Mitral valve disease of degenerative or ischemic etiology affects 7.5 and 9.3% of population older than 65 and 75 years, respectively. "Open" (with cardiopulmonary bypass) surgical repair or valve replacement are not possible in almost half of affected patients because of their complications and concomitant diseases responsible for extremely high risk of these interventions. In the last decade, minimally invasive endovascular technology - transcatheter aortic valve implantation (TAVI) - has been widely introduced for correction of aortic valve disease in similar category of patients. However, transcatheter mitral valve implantation (TMVI) has been developed just during recent couple of years.
No takes yet. Share an insight, caveat, or question.
Zhuravleva et al. (2017) conducted a review in Mitral valve disease. Transcatheter mitral valve implantation (TMVI) was evaluated. Transcatheter mitral valve implantation (TMVI) has emerged in recent years as a minimally invasive alternative for patients with mitral valve disease who are at extremely high risk for open surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: